Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAB-005
- Development stage
- Preclinical
- Lead developer
- Zhongshan Laibo Ruichen Biopharmaceutical
- Modality
- Peptides
- Administration
- Intraarticular
01
Overview
RAB-005 is a preclinical-stage dual-action peptide therapeutic being developed by ZhongShan LaiBo RuiChen BioMedicine (Rabpharma) for the treatment of osteoarthritis. The drug is engineered to exhibit both anti-inflammatory and chondro-promoting (cartilage-promoting) activities, aiming to address both the inflammatory symptoms and the underlying structural cartilage damage associated with the disease. It is designed for intra-articular administration, allowing for localized delivery directly into the affected joint. RAB-005 is currently in the discovery and preclinical phase of development as part of a broader pipeline targeting bone and joint health.
Beyond the preview
Go deeper on RAB-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAB-005.